Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis.

Published in: Drug design, development and therapy (2019)

Results suggest that denosumab is superior to bisphosphonates in its effects on lumbar spine and total hip BMD in patients with GIOP. There was no difference in the incidence of infections, adverse events or serious adverse events. Studies were underpowered to detect differences in the risk of fracture. Denosumab is a reasonable option for treatment of GIOP. However, further studies are needed to guide transitions off denosumab.

Keyphrases

bone mineral density
total hip
giant cell
postmenopausal women
total knee arthroplasty
body composition
risk factors
high glucose
oxidative stress
endothelial cells
diabetic rats